This site is intended for
Healthcare Professionals only.

For Patients


NLRP3 activity expressed in a Dendritic cell diagram

Nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) is involved in the assembly of the NLRP3 inflammasome, leading to enhanced antitumor response.

  • NLRP3 is a protein expressed in antigen-presenting cells (APCs) such as dendritic cells (DCs), monocytes, and macrophages1
  • NLRP3 is involved in the assembly of the NLRP3 inflammasome, a key mediator of innate immunity and priming of T cells2,3
    • NLRP3 expression is first induced by inflammatory signals4
      • Specifically, NLRP3 expression and activation requires 2 separate inflammatory signals. Full activation of the inflammasome may be restricted to sites of inflammation, potentially avoiding damage to healthy cells5,6
  • Factors released during tumor cell death, such as adenosine triphosphate (ATP), trigger assembly of the NLRP3 inflammasome, which then converts inactive IL-1β and IL-18 into their mature, active forms3,7,8
  • These cytokines initiate APC priming as well as NK- and cytotoxic T-cell activation, leading to increased recruitment and antitumor function of these primary effector cells2,3,9-12

Get I-O Resources

Order or download
educational tools for your
patients and practice

See all resources

Clinical Trials

Learn more about our
current clinical trials

Learn more


1. Guarda G, Zenger M, Yazdi AS, et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol. 2011;186(4):2529-2534. 2. Dupaul-Chicoine J, Arabzadeh A, Dagenais M, et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity. 2015;43(4):751-763. 3. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170-1178. 4. Shao B-Z, Xu Z-Q, Han B-Z, Su D-F, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262. doi:10.3389/fphar.2015.00262. 5. Embry CA, Franchi L, Nuñez G, Mitchell TC. Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci Signal. 2011;4(171):ra28. doi:10.1126/scisignal.2001486. 6. Sharma D, Kanneganti T-D. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol. 2016;213(6):617-629. 7. Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22(1):23-32. 8. He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012-1021. 9. Ben-Sasson SZ, Hogg A, Hu-Li J, et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med. 2013;210(3):491-502. 10. Maltez VI, Tubbs AL, Cook KD, et al. Inflammasomes coordinate pyroptosis and natural killer cell cytotoxicity to clear infection by a ubiquitous environmental bacterium. Immunity. 2015;43(5):987-997. 11. Freeman BE, Hammarlund E, Raué H-P, Slifka MK. Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A. 2012;109(25):9971-9976. 12. Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA. Interleukin-1β costimulates interferon-γ production by human natural killer cells. Eur J Immunol. 2001;31(3):792-801. 13. Chow MT, Sceneay J, Paget C, et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 2012;72(22):5721-5732.